---
title: Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in
  preclinical models of hematologic malignancy
date: '2024-01-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38211332/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240112170537&v=2.18.0
source: Blood
description: Venetoclax, the first-generation inhibitor of the apoptosis regulator
  B-cell lymphoma 2 (BCL2), disrupts the interaction between BCL2 and pro-apoptotic
  proteins, promoting the apoptosis in malignant cells. Venetoclax is the mainstay
  of therapy for relapsed chronic lymphocytic leukemia (CLL) and is under investigation
  in multiple clinical trials for the treatment of various cancers. Although venetoclax
  treatment can result in high rates of durable remission, relapse has been widely
  ...
disable_comments: true
---
Venetoclax, the first-generation inhibitor of the apoptosis regulator B-cell lymphoma 2 (BCL2), disrupts the interaction between BCL2 and pro-apoptotic proteins, promoting the apoptosis in malignant cells. Venetoclax is the mainstay of therapy for relapsed chronic lymphocytic leukemia (CLL) and is under investigation in multiple clinical trials for the treatment of various cancers. Although venetoclax treatment can result in high rates of durable remission, relapse has been widely ...